Approval secured by Simplera Sync sensor designed for MiniMed 780G insulin pump from the Food and Drug Administration.
Medtronic, the global leader in medical technology, is set to revolutionise diabetes management with the introduction of the Simplera Sync sensor for its MiniMed 780G system. This innovative device promises to offer a more compact, user-friendly Continuous Glucose Monitoring (CGM) experience.
A Compact, User-Friendly CGM Experience
The Simplera Sync sensor boasts a small, flat, square form factor with rounded corners, making it half the size of the previous Guardian 4 sensor. This compact design allows for wearing on the back of the upper arm, providing greater comfort and convenience. Key features of the Simplera Sync sensor include:
- No fingerstick calibration required
- A 2-hour warm-up time
- 7 days of wear time
- Alarms for low and high glucose levels
- Data accessible via Android and iPhone apps
- Compatibility with MiniMed 780G for automated insulin delivery (AID) integration
Improved Diabetes Management
The benefits of the Simplera Sync sensor extend beyond its smaller, less bulky design. By seamlessly integrating real-time glucose data into the MiniMed 780G system, it enables automated insulin adjustments, improving glycemic control and reducing manual management burden. Real-world data shows global users consistently achieve time in range above international targets of 70% when using optimal settings with the MiniMed 780G system.
Revolutionary Features
The MiniMed 780G system is the only system featuring Meal Detection technology, which detects rising sugar levels and delivers more insulin as needed. It also offers more flexibility for users of the company's most advanced insulin delivery system, allowing them to experience 96% fewer injections compared to multiple daily injections. The system's adaptive algorithm automatically adjusts glucose levels every 5 minutes, 24/7.
A Step Towards Innovation
Medtronic's commitment to driving innovation that makes life easier for those living with diabetes is evident in the development of the Simplera Sync sensor. Que Dallara, Medtronic's EVP and president of Medtronic Diabetes, has stated that the company is dedicated to pushing the boundaries of technology to improve patient outcomes and quality of life.
The Simplera Sync sensor's limited launch in the U.S. is scheduled for the fall of 2025, with the MiniMed 780G system already receiving CE Mark and FDA approval. As of now, the MiniMed 780G system is compatible with the Guardian 4 sensor, but the recent FDA approval of the Simplera Sync sensor for use with the MiniMed 780G system marks a significant step forward in diabetes management technology.
[1] Medtronic. (n.d.). Simplera Sync Sensor. Retrieved from https://www.medtronicdiabetes.com/products/continuous-glucose-monitoring/simplera-sync-sensor
[3] Medtronic. (n.d.). MiniMed 780G System. Retrieved from https://www.medtronicdiabetes.com/products/insulin-pumps/minimed-780g-system
The Simplera Sync sensor's integration with the MiniMed 780G system showcases the potential of digital health, leveraging science to revolutionize medical-conditions management related to diabetes. This advancement promises improved health-and-wellness outcomes for those living with the condition, reflecting Medtronic's unwavering commitment to innovation in health-and-wellness and medical-conditions treatment.
